Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESPB vs Morphine in Breast Cancer Surgery
NCT05429489Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, triple-blind trial of bupivacaine hydrochloride 0.75% injection in postoperative pain (3 arms), sponsored by National Cancer Institute. Primary endpoint: Total Postoperative Analgesic Consumption at 24 hours. Started Jun 2022; status: completed.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05429489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429489.